B. Metzler seel. Sohn & Co. AG lessened its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 10.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 62,198 shares of the company's stock after selling 7,141 shares during the period. B. Metzler seel. Sohn & Co. AG owned about 0.07% of HealthEquity worth $5,968,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the company. Cerity Partners LLC lifted its holdings in shares of HealthEquity by 15.1% in the third quarter. Cerity Partners LLC now owns 17,259 shares of the company's stock valued at $1,413,000 after purchasing an additional 2,258 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in HealthEquity by 165.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 20,437 shares of the company's stock worth $1,673,000 after acquiring an additional 12,745 shares in the last quarter. Townsquare Capital LLC boosted its position in HealthEquity by 3.9% during the 3rd quarter. Townsquare Capital LLC now owns 22,292 shares of the company's stock worth $1,825,000 after acquiring an additional 839 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of HealthEquity by 28.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,526 shares of the company's stock valued at $1,844,000 after purchasing an additional 4,993 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of HealthEquity by 1.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 329,477 shares of the company's stock worth $26,968,000 after purchasing an additional 6,197 shares in the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
HQY has been the subject of a number of research reports. Barrington Research reissued an "outperform" rating and set a $112.00 target price on shares of HealthEquity in a research note on Friday, March 14th. KeyCorp cut their price target on HealthEquity from $120.00 to $110.00 and set an "overweight" rating for the company in a research note on Monday, March 24th. The Goldman Sachs Group dropped their price objective on HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a report on Thursday, March 27th. Raymond James raised shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and decreased their target price for the stock from $120.00 to $115.00 in a research report on Tuesday, March 25th. Finally, Royal Bank of Canada lifted their price objective on shares of HealthEquity from $100.00 to $105.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $112.58.
Check Out Our Latest Report on HealthEquity
Insider Buying and Selling
In related news, Director Robert W. Selander sold 5,750 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the completion of the transaction, the director now directly owns 78,219 shares of the company's stock, valued at $8,704,992.51. This trade represents a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.20% of the stock is owned by company insiders.
HealthEquity Stock Performance
HQY stock traded down $4.48 on Friday, reaching $78.49. 1,344,078 shares of the company were exchanged, compared to its average volume of 738,748. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. HealthEquity, Inc. has a 12 month low of $65.01 and a 12 month high of $115.59. The stock's fifty day moving average price is $102.22 and its 200 day moving average price is $96.21. The firm has a market capitalization of $6.79 billion, a PE ratio of 72.13, a PEG ratio of 1.60 and a beta of 0.49.
HealthEquity Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Recommended Stories
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
